From trials to practice: A 2025 review of idecabtagene vicleucel and ciltacabtagene autoleucel efficacy across clinical studies and real-world evidence

This article focuses on the FDA-approved treatments idecabtagene vicleucel and ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. These therapies have demonstrated exceptional effectiveness, achieving high overall response rates in pivotal trials like KarMMa-1 and CARTITUDE-1 and significantly improving progression-free survival compared to traditional treatments. Real-world evidence confirms their efficacy and manageable safety across diverse patient populations, although key toxicities include cytokine release syndrome and neurotoxicity.